NcXHF

CURRENT STANDARDS AND CLINICAL TRIALS IN STAGE III NSCLC
advanced non-small-cell lung cancer? A pooled analysis of the literature.
J Thorac Oncol. 2013;8:1181-1189.
21. Dinan MA, Curtis LH, Carpenter WR, et al. Stage migration, selection
bias, and survival associated with the adoption of positron emission tomography
among Medicare benefıciaries with non-small-cell lung cancer.
J Clin Oncol. 2012;30:2725-2730.
22. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance
gefıtinib or placebo after concurrent chemoradiotherapy and docetaxel
consolidation in inoperable stage III non-small-cell lung cancer: SWOG
S0023. J Clin Oncol. 2008;26:2450-2456.
23. Wozniak AJ, Moon J, Thomas CR, et al. SWOG S0533: a pilot trial of
cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation
docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts
of patients (pts) with inoperable locally advanced stage III non-small
cell lung cancer (NSCLC). J Clin Oncol. 2012;30 (suppl; abstr 7018).
24. Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fıstula
formation in patients with lung cancer treated with chemoradiation and
bevacizumab. J Clin Oncol. 2009;28:43-48.
25. Lu C, Lee JJ, Komaki R, et al. Chemoradiotherapy with or without AE-
941 in stage III non-small cell lung cancer: a randomized phase III trial.
J Natl Cancer Inst. 2010;102:859-865.
26. Hoang T, Dahlberg SE, Schiller JH, et al. Randomized phase III study of
thoracic radiation in combination with paclitaxel and carboplatin with
or without thalidomide in patients with stage III non-small-cell lung
cancer: the ECOG 3598 study. J Clin Oncol. 2012;30:616-622.
27. Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of
radiation-induced DNA damage. Clin Cancer Res. 2007;13:6555-6560.
28. Das AK, Chen BP, Story MD, et al. Somatic mutations in the tyrosine
kinase domain of epidermal growth factor receptor (EGFR) abrogate
EGFR-mediated radioprotection in non-small cell lung carcinoma.
Cancer Res. 2007;67:5267-5274.
29. Sun Y, Nowak KA, Zaorsky NG, et al. ALK inhibitor PF02341066
(crizotinib) increases sensitivity to radiation in non-small cell lung
cancer expressing EML4-ALK. Mol Cancer Ther. 2013;12:696-704.
30. McKenna WG, Muschel RJ, Gupta AK, et al. The RAS signal transduction
pathway and its role in radiation sensitivity. Oncogene. 2003;22:
5866-5875.
31. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus
placebo after chemoradiotherapy for stage III non-small-cell lung cancer
(START): a randomized, double blind, phase 3 trial. Lancet Oncol.
2014;15:59-68.
32. Tang C, Wang X, Soh H, et al. Combining radiation and immunotherapy:
a new systemic therapy for solid tumors? Cancer Immunol Res.
2014;2:831-838.
33. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment
synergistically promote antitumor immunity in mice. J Clin Invest.
2014;124:687-695.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e447